Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Takeda Pharmaceutical Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 3/6
Takeda Pharmaceutical has a total shareholder equity of ¥7,799.2B and total debt of ¥5,481.0B, which brings its debt-to-equity ratio to 70.3%. Its total assets and total liabilities are ¥16,227.7B and ¥8,428.5B respectively. Takeda Pharmaceutical's EBIT is ¥509.2B making its interest coverage ratio 5.1. It has cash and short-term investments of ¥804.3B.
Anahtar bilgiler
70.3%
Borç/özkaynak oranı
JP¥5.48t
Borç
| Faiz karşılama oranı | 5.1x |
| Nakit | JP¥804.27b |
| Eşitlik | JP¥7.80t |
| Toplam yükümlülükler | JP¥8.43t |
| Toplam varlıklar | JP¥16.23t |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: TKD's short term assets (¥3,107.5B) exceed its short term liabilities (¥2,465.2B).
Uzun Vadeli Yükümlülükler: TKD's short term assets (¥3,107.5B) do not cover its long term liabilities (¥5,963.2B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: TKD's net debt to equity ratio (60%) is considered high.
Borcun Azaltılması: TKD's debt to equity ratio has reduced from 116% to 70.3% over the past 5 years.
Borç Kapsamı: TKD's debt is not well covered by operating cash flow (14.5%).
Faiz Kapsamı: TKD's interest payments on its debt are well covered by EBIT (5.1x coverage).